# José Baselga

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jose-baselga-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 76,858 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 110 |
| i10-index | 245 |
| Last Known Institution | Weatherford College |
| OpenAlex ID | https://openalex.org/A5113670835 |
| Works | 368 |

## Researcher papers

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [The landscape of somatic copy-number alteration across human cancers](https://scholariq.org/papers/the-landscape-of-somatic-copy-number-alteration-across-human-cancers/)
- [Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015](https://scholariq.org/papers/tailoring-therapies-improving-the-management-of-early-breast-cancer-st-gallen/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.](https://scholariq.org/papers/anti-her2-immunoliposomes-enhanced-efficacy-attributable-to-targeted-delivery/)
- [BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors](https://scholariq.org/papers/bim-expression-in-treatment-naive-cancers-predicts-responsiveness-to-kinase/)
- [Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer](https://scholariq.org/papers/phase-iii-trial-evaluating-the-addition-of-paclitaxel-to-doxorubicin-followed-by/)
- [Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy](https://scholariq.org/papers/feasibility-and-tolerability-of-sequential-doxorubicin-paclitaxel-followed-by/)
- [Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma](https://scholariq.org/papers/selective-inhibition-of-hdac3-targets-synthetic-vulnerabilities-and-activates/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Weatherford College](https://scholariq.org/institutions/weatherford-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.